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Background: Outcome of Mycobacterium tuberculosis (Mtb) infection is affected by virulence of the infecting strain
of Mtb, host environment, co-morbidities, and the genetic composition of the host, specifically the presence or
absence of genes involved in immune responses/regulation. It is hypothesized that specific killer immunoglobulin-like
receptor (KIR) genes may be associated with Mtb infection and clinical outcome. This cross-sectional study examined
the KIR gene frequencies, profiles, and haplotypes of individuals with active tuberculosis, latent tuberculosis infection,
compared to TB and HIV negative healthy controls.
Results: Analysis of KIR gene frequencies revealed differences among disease status groups, suggesting that
enrichment or depletion of specific KIR genes may direct the disease outcome. Mtb infected individuals were
more likely to have a centromeric-AA haplotype compared to controls.
Conclusion: The differences in KIR gene frequencies and haplotypes may result in differential cytokine expression,
contributing to different disease outcomes, and suggest a genetic influence on Mtb susceptibility and pathogenesis.
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Tuberculosis (TB) incidence in the world and in Canada
overall are declining toward goals set by the World
Health Organization [1], however, certain populations
and/or regions within Canada continue to have rates of
tuberculosis exceeding the national average. In 2012, the
global burden of TB was estimated at 8.6 million incident
cases (122/100,000 population) [1]. Canada reported 1686
new active cases of TB (4.8/100,000) in 2012 [2]. The inci-
dence of TB in Manitoba was more than twice the na-
tional rate at 138 cases (10.9/100,000).
The immune response to an intracellular pathogen
such as Mycobacterium tuberculosis (Mtb) involves natural
killer (NK) cells to bridge the innate and adaptive immune
response to infection [3]. NK cells are important in early* Correspondence: Meenu.Sharma@phac-aspc.gc.ca
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creativecommons.org/publicdomain/zero/1.0/Mtb infection, as they are capable of activating phagocytic
cells at the site of infection [4], and are producers of
INF-γ, which functions to activate macrophages [5].
The activity of NK cells is controlled by a balance of in-
hibitory and stimulatory signals generated when human
leukocyte antigen (HLA) class I ligands bind to killer
immunoglobulin-like receptors (KIRs) on the NK cell
surface [6]. This highly specific recognition system is
controlled by the integration of signals generated by a
multitude of inhibitory and activating KIRs, which in-
hibit or activate, respectively, cytotoxicity and secretion
of cytokines ultimately leading to death of the targeted
cell [7]. Both inhibition and activation involve a number
of signalling molecules, as previously described [8, 9].
There is extensive genomic diversity in KIR genes in
humans. Currently, a database and online repository for
immune gene frequencies in worldwide populations re-
ports 517 different KIR genotypes [10, 11]. It is believed
that this variation may affect resistance or susceptibilityicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Sample demographics
Parameter Value Number Percent
Gender Male 91 43.5
Female 118 56.5
Age ≤19 0 0
20 - 39 88 42.1
40 - 59 105 50.2
≥60 16 7.7
Disease status Control 104 49.8
LTBI 46 22
ATB 59 28.2








LTBI Latent tuberculosis infection; ATB Active tuberculosis
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actions and the downstream signalling and/or cytokine
release that follows [12, 13]. Genetic susceptibility or
resistance to infectious diseases, in conjunction with
environmental and host risk factors, is thought to deter-
mine disease progression [14–16].
Present literature indicates that the outcome of Mtb
infection is affected not only by virulence of the infecting
strain of M. tuberculosis [17], but also by host environ-
ment, disease co-morbidities, and the genetic composition
of the host, specifically the presence or absence of genes
that regulate the immune system [14, 16, 18–20]. Fol-
lowing Mtb infection, approximately 10 % of individuals
will develop active TB (ATB) during their lifetime, while
the majority of individuals will exhibit latent TB infec-
tion (LTBI) [21, 22]. LTBI refers to the condition in
which Mtb remains viable in the macrophage but re-
tains a small amount of metabolic activity [23]. It is not
currently known which genes and/or immune compo-
nents regulate an individual’s disease outcome following
exposure (ATB, LTBI, or exposed uninfected). Present
literature captures only those studies focusing on gen-
etic profiles among active tuberculosis vs. uninfected
individuals. In the majority of these studies, the control
group contains both individuals with LTBI infection as
identified by a positive Tuberculin skin test (TST), and
those with uninfected status.
The novel aspect of this study is to identify unique
profiles among the LTBI population, diagnosed using the
Interferon gamma release assay (IGRA)' as there is identify
twice in this sentence. Differences in KIR profiles and
haplotypes may be associated with Mtb infection status
[24–26] and play a role in altered TB disease progression
and disease outcomes. In this cross-sectional study, we
examined the enrichment or depletion of KIR genes in
individuals from Manitoba with ATB infection, LTBI and
controls, and further explored the association between
Mtb infection status and KIR profiles and haplotypes.
Methods
Sample Populations
The 209 samples consisted of whole blood from individ-
uals living in Manitoba. The sampling was performed
at hospital and community TB clinics in Winnipeg,
Manitoba, Canada between November 3, 2009 and
March 29, 2011 and was cross-sectional in nature. The
study was approved by the Health Research Ethics
Board at the University of Manitoba (H2008:301). All
study participants provided written informed consent
following consultation with a study nurse. ATB infec-
tion (n = 59) was confirmed by mycobacterial culture.
LTBI (n = 46) was identified using the interferon-gamma
release assay (IGRA) (QuantiFERON®-TB-Gold, Qiagen).
Healthy IGRA negative HIV negative individuals (n = 104)were used as controls and consisted largely of individ-
uals participating in routine occupational health screen-
ing, and immigration screening. All individuals within
the specified time period who consented to genetic
testing were included in this study. Exclusion criteria in-
cluded those individuals with HIV co-infection, and
anyone who exhibited an indeterminate IGRA response.
Participant demographics for ethnicity, age, and gender
can be seen in Table 1.
DNA extraction and replication
Genomic DNA was extracted using Qiagen DNA Mini
Kit as per manufacturer’s instructions (Qiagen, Louisville,
KY). The samples were subjected to whole genome rep-
lication using the Qiagen Repli-G mini kit as per manu-
facturer’s instructions to increase DNA concentration
of the testing sample.
KIR genotyping
The concentration of DNA was normalized to 100 μg/mL
at 260 nm using the SmartSpec Plus spectrophotometer
(Bio-Rad, Mississauga, ON). KIR genotyping was
performed by sequence-specific primer polymerase
chain reaction using the Miltenyi Biotec KIR Typing
Kit (Auburn, CA) as previously described [9]. The
amplicons were visualized with UV light (Bio-Rad Gel
Doc EZ Imager, Mississauga, ON) following gel elec-
trophoresis at 13 V/cm on a 2 % agarose gel containing
ethidium bromide. The KIR typing kit allows for
Braun et al. BMC Genetics  (2015) 16:63 Page 3 of 7detection of all known human KIR genes and alleles
[27, 28]. KIR2DL5A and KIR2DL5B are collectively
referred to as KIR2DL5 for this paper.
Statistical analysis
Data for each individual was entered into BioNumerics
software version 5.0 (Applied Maths, Belgium) as binary
character data. All KIR genes were combined into a
single KIR profile for each individual and clustered to
identify prevalent profiles among specified groups using
the categorical co-efficient and unweighted pair group
method with arithmetic mean (UPGMA) [29]. KIR gene
frequencies were tabulated by direct counts from the
clustered profiles to determine frequency within a de-
fined group. Differences between Mtb infection status
groups were estimated using the two-tailed Fisher’s exact
test (GraphPad Software, La Jolla, CA). A P-value ≤0.05
was considered statistically significant. Haplotype desig-
nation was determined as previously described [9].
Results
KIR gene frequencies
In order to determine the differences in KIR gene fre-
quencies between different disease status groups (ATB,
LTBI, and controls), the KIR gene frequency data ob-
tained was analyzed and compared. All 209 samples con-
sistently contained the framework genes KIR2DL4,
KIR3DL2, KIR3DL3, and the pseudogenes KIR2DP1 and
KIR3DP1.
Five KIR genes (KIR2DL2, KIR2DL5, KIR2DL5B,
KIR2DS2, and KIR2DS3) differed significantly (P ≤ 0.05)
in frequency between disease status groups (Table 2).
Two genes differed between individuals with Mtb infec-
tion (LTBI and ATB) vs. controls, KIR2DL2 (33.33 % vs.
55.77 %, P = 0.0014) and KIR2DS2 (34.29 % vs. 54.81 %,
P = 0.0035). However, the underlying differences can be
exposed when analyzing LTBI and ATB separately.
KIR2DL5 and KIR2DL5B (both 73.91 % vs. 51.92 %, P =
0.0125) were present in higher frequency in individuals
within the LTBI group as compared to controls.
KIR2DL2 (27.12 % vs. 55.77 %, P = 0.0005), KIR2DS2
(27.12 % vs. 54.82 %, P = 0.0010), and KIR2DS3 (8.47 %
vs. 30.77 %, P = 0.0009) were present in a lower fre-
quency in individuals with ATB compared to controls.
Lastly, gene frequencies of KIR2DL5 (73.91 % vs.
49.15 %, P = 0.0156), KIR2DL5B (73.91 % vs. 49.15 %,
P = 0.0156), and KIR2DS3 (39.13 % vs. 8.47 %, P = 0.0002)
differed significantly between latently and actively infected
individuals, respectively.
KIR gene profiles
Forty-three KIR profiles (genotypes) were identified in
this study (Fig. 1). These profiles ranged in their fre-
quency of distribution from as high as 24.88 % (52/209)to as low as 0.48 % (1/209). Twenty-two of the 43 pro-
files identified were unique to a single individual. The
most prominent genotypes were #7, (18/209, 8.2 %), #8
(52/209, 24.9 %), #12 (11/209, 5.3 %), #18 (12/209,
5.7 %), and #36 (25/209, 12.0 %). Eight KIR genotypes
were shared between all three disease status groups (ATB,
LTBI, controls; genotypes # 7, 8, 12, 17, 18, 30, 36, 39)
(Fig. 2). Excluding those shared with individuals from the
control group, two genotypes were shared between the
LTBI and ATB groups (genotypes #11, 22). Nineteen ge-
notypes were exclusive to the control group. Five geno-
types were exclusive to those individuals with ATB
(genotypes #1, 4 9, 23, 37), and represented 6/59
(10.2 %) active cases. Three genotypes were exclusive to
those individuals with LTBI (genotypes # 13, 21, 28),
and represented 3/46 (6.5 %) latent cases.
Those individuals with Mtb infection (LTBI or ATB)
were found within 25 of the 43 genotypes, most predom-
inantly in #8 (25/105, 23.8 %) and #36 (20/105, 19.0 %).
Over 42 % of Mtb infected individuals were found in
these two genotypes.
Haplotype analysis
In addition to gene frequency variation, there is haploty-
pic variation due to the different number and kinds of
KIR genes [30]. Both LTBI (34.8 %, P = 0.0004) and ATB
(32.3 %, P = 0.0005) infected individuals were signifi-
cantly more likely to have AA-AB haplotypes than con-
trols (9.6 %; Table 3). Additionally, those individuals
with ATB were less likely to have an AB-AB haplotype
compared to controls (8.5 % vs. 21.2 %, P = 0.0476). The
majority of the Mtb infected cases are represented in the
AA-AA (LTBI – 21.7 %, ATB – 35.6 %) and AA-AB
(LTBI – 34.8 %, ATB – 32.3 %) haplotypes. Overall,
66.67 % of Mtb infected individuals had a centromeric-
AA haplotype (LTBI – 58.7 %, ATB – 72.9 %), compared
with only 44.2 % of controls (P = 0.0014).
Discussion
This study was designed to investigate the KIR gene fre-
quencies in individuals from Manitoba with ATB, LTBI,
and a control group, as described in methods. Addition-
ally, KIR profiles and haplotypes were analyzed. KIR
genes may influence disease outcome (latent vs. active)
which is controlled in part by an organized immune
response.
When determining KIR gene frequencies, framework
genes and pseudogenes were present in 100 % of the
samples, as expected [31]. KIR2DL2, KIR2DL5, KIR2DL5B,
KIR2DS2, and KIR2DS3 differed significantly between Mtb
status groups.
Mahfouz et al. and Mendez et al. both found KIR2DL3
to be the only statistically significant KIR gene frequency
to differ between ATB patients and controls (higher in
Table 2 Killer immunoglobulin-like receptor (KIR) gene frequencies by tuberculosis status
KIR; n (% f)
2DL1 2DL2 2DL3 2DL4 2DL5all 2DL5A 2DL5B 2DS1 2DS2 2DS3 1D 2DS4 2DS5 3DL1 3DL2 3DL3 3DS1 2DP1 3DP1
Mtb Infected



























































































































































1.0000 0.0014 0.2837 1.0000 0.2664 0.5776 0.2664 0.4879 0.0035 0.1599 0.3519 0.4976 0.2463 0.7832 1.0000 1.0000 0.1279 1.0000 1.0000
LTBI vs. Control 1.0000 0.1137 1.0000 1.0000 0.0125 0.2853 0.0125 0.2141 0.2190 0.3505 0.8363 1.0000 0.7050 0.4357 1.0000 1.0000 0.1099 1.0000 1.0000
ATB vs. Control 1.0000 0.0005 0.0957 1.0000 0.7472 1.0000 0.7472 1.0000 0.0010 0.0009 0.1047 1.0000 0.1716 0.7583 1.0000 1.0000 0.4121 1.0000 1.0000
ATB vs. LTBI 1.0000 0.1474 1.0000 1.0000 0.0156 0.3237 0.0156 0.2432 0.0988 0.0002 0.0933 1.0000 0.5457 0.2272 1.0000 1.0000 0.5552 1.0000 1.0000













1 9 5 2 2 0.48  (1) 0.95  (1) 1.69  (1)
2 10 5 3 2 0.48  (1) 0.96  (1)
3 11 6 3 2 0.48  (1) 0.96  (1)
4 14 7 5 2 0.48  (1) 0.95  (1) 1.69  (1)
5 13 7 4 2 0.48  (1) 0.96  (1)
6 11 7 2 2 0.96  (2) 0.95  (1) 1.69  (1) 0.96  (1)
7 12 7 3 2 8.16  (18) 4.76  (5) 6.78  (4) 2.17  (1) 12.5  (13)
8 10 6 2 2 24.88  (52) 23.81  (25) 27.12  (16) 19.57  (9) 26.0  (27)
9 11 6 3 2 0.48  (1) 0.95  (1) 1.69  (1)
10 9 6 1 2 0.48  (1) 0.96  (1)
11 10 6 2 2 0.96  (2) 1.90  (2) 1.69  (1) 2.17  (1)
12 9 6 1 2 5.26  (11) 5.71  (6) 8.47  (5) 2.17  (1) 4.8  (5)
13 14 7 5 2 0.48  (1) 0.95  (1) 2.17  (1)
14 16 9 5 2 0.48  (1) 0.96  (1)
15 16 8 6 2 0.48  (1) 0.96  (1)
16 17 9 6 2 0.48  (1) 0.96  (1)
17 14 9 3 2 1.44  (3) 1.90  (2) 1.69  (1) 2.17  (1) 0.96  (1)
18 15 9 4 2 5.74  (12) 5.71  (6) 3.39  (2) 8.70  (4) 5.8  (6)
19 16 10 4 2 0.48  (1) 0.96  (1)
20 14 8 4 2 1.44  (3) 1.90  (2) 4.35  (2) 0.96  (1)
21 13 8 3 2 0.48  (1) 0.95  (1) 2.17  (1)
22 15 9 4 2 0.96  (2) 1.90  (2) 1.69  (1) 2.17  (1)
23 16 9 5 2 0.48  (1) 0.96  (1)
24 16 9 5 2 0.96  (2) 1.90  (2) 3.39  (2)
25 17 9 6 2 1.44  (3) 2.9  (3)
26 16 8 6 2 0.48  (1) 0.96  (1)
27 18 10 6 2 3.83  (8) 1.90  (2) 4.35  (2) 5.8  (6)
28 17 9 6 2 0.48  (1) 0.95  (1) 2.17  (1)
29 18 10 6 2 0.96  (2) 1.9  (2)
30 17 10 5 2 4.31  (9) 3.81  (4) 5.08  (3) 2.17  (1) 4.8  (5)
31 19 10 7 2 0.48  (1) 0.96  (1)
32 18 9 7 2 0.48  (1) 0.96  (1)
33 17 9 6 2 0.96  (2) 1.9  (2)
34 18 10 6 2 4.78  (10) 4.76  (5) 10.87  (5) 4.8  (5)
35 16 9 5 2 0.48  (1) 0.96  (1)
36 16 9 5 2 11.96  (25) 19.04  (20) 20.34  (12) 17.39  (8) 4.8  (5)
37 15 8 5 2 0.48  (1) 0.95  (1) 1.69  (1)
38 14 8 4 2 2.87  (6) 3.81  (4) 5.08  (3) 2.17  (1) 1.9  (2)
39 15 9 4 2 3.35  (7) 5.71  (6) 6.78  (4) 4.35  (2) 0.96  (1)
40 16 10 4 2 0.48  (1) 0.96  (1)
41 15 8 5 2 0.48  (1) 0.96  (1)
42 15 9 4 2 0.96  (2) 0.95  (1) 2.17  (1) 0.96  (1)
43 16 9 5 2 2.87  (6) 2.86  (3) 6.52  (3) 2.9  (3)
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Fig. 1 Frequency of KIR genotypes in study group population. Forty-three distinct KIR types were seen in these 209 individuals that differ from
each other by the presence of (shaded box) or absence (white box) of 19 KIR genes (KIR2DL5 broken down into 2DL5A, 2DL5B, and 2DL5 (both A
and B); KIR2DS4 broken down into 1D and full length 2DS4). Frequency (%F) of each genotype is expressed as a percentage and is defined as the
number of individuals having the genotype (N+) divided by the number of individuals (n) in the tuberculosis status group
13, 21, 28 
2, 3, 5, 10, 14, 15, 16, 
19, 23, 25, 26, 29, 31, 
32, 33, 35, 40, 41 
1, 4, 9, 24, 37 
20, 27, 34, 
42, 43 
11, 22 
7, 8, 12, 
17, 18, 30, 




Fig. 2 Distribution of KIR genotypes among active tuberculosis
(ATB), latent tuberculosis infection (LTBI), and controls. Content of
each genotype can be seen in Fig. 1
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In our study, KIR2DL3 occurred in only a slightly
higher frequency of individuals with ATB (98.31 %) com-
pared to controls (91.35 %, P = 0.0957; NS). Pydi et al.
found gene frequencies of KIR2DS1, KIR2DS5, KIR3DL1,
and KIR2DL3 to be higher in ATB patients compared
to controls (P < 0.0001) [32]. Although KIR2DS5 and
KIR2DL3 gene frequencies differed slightly between ATB
and control groups in our study, none of the observed
differences were statistically significant. Lastly, Lu et al.
found gene frequencies of KIR2DS1, KIR2DS3, and
KIR3DS1 to be significantly higher in ATB patients com-
pared to controls (P < 0.05) [33]. In our study, frequencies
of KIR2DS1 and KIR3DS1 were not statistically different
between those with ATB compared to controls. However,
when looking at KIR2DS3, our study showed a decreased
frequency in individuals with ATB compared controls
(8.47 % vs. 30.77 %, P = 0.0009). Observed differences in
KIR frequencies between TB status groups may be due in
large part to ethnicity, as in each of the above mentioned
studies, a different country of origin was involved, and
Table 3 Frequency of centromeric and telomeric haplotypes by
tuberculosis status
Haplotype Tuberculosis Status; n (%F)
Latent Active Control
Centromeric Telomeric (n = 46) (n = 59) (n = 104)
AA AA 10 (21.7) 21 (35.6) 33 (31.73)
AA AB 16 (34.8) 19 (32.3) 10 (9.62)a,b
AB AA 6 (13.0) 8 (13.6) 24 (23.08)
AB AB 9 (19.6) 5 (8.5) 22 (21.15)b
AA BB 1 (2.2) 3 (5.1) 3 (2.88)
AB BB 2 (3.4) 3 (2.88)
BB AA 4 (8.7) 1 (1.7) 4 (3.85)
BB AB 4 (3.85)
BB BB 1 (0.96)
aSignificant compared latent TB; bSignificant compared to active TB; p-value ≤
0.05 considered significant
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that the Manitoba population is very heterogeneous con-
sisting of many foreign born immigrant individuals, as well
as indigenous and Canadian born populations, future
studies matching TB status groups by ethnicity will help
to more clearly define the role of KIR genes in TB patho-
genicity. Additionally, group definitions may have played a
role; the control groups in the above published studies
contained either TST positive individuals or had no data
on TB reactivity. These control group then reflect a mix-
ture of both uninfected and LTBI infected participants. In
contrast to this, with the use of the IGRA testing, we were
able to clearly distinguish our LTBI and control groups.
With the exception of KIR2DL2, our study found an in-
creased presence of inhibitory KIR (KIR2DL5, KIR2DL5B)
in LTBI individuals and a decreased presence of activating
KIR (KIR2DS2, KIR2DS3) in ATB infected individuals.
This may suggest that the enrichment or depletion of
specific KIR genes predisposes an individual to progres-
sing to ATB disease by means of an inadequate cytotoxic
response to the pathogen. LTBI refers to the condition in
which Mtb remains viable in the macrophage but only re-
tains a small amount of metabolic activity [23]. The inabil-
ity of the immune system to maintain the infection in a
latent state results in ATB infection.
Forty-three different gene profiles were identified in
the 209 samples, of which, 25 profiles contained Mtb
cases. The profiles containing the most Mtb cases were
also prevalent in the control group, suggesting an
unlikely correlation between profile/genotype and TB
status. Many profiles were unique to individuals with
Mtb, however there is little to be concluded from those
profiles containing only a few individuals. Extrapolation
of these findings via continued sampling is warranted to
determine the importance of KIR profiles.Those individuals with LTBI and ATB were more
likely to have an AA-AB haplotype than controls. This
was the haplotype that contained the most Mtb cases
(35/105, 33.3 %). Two-thirds (66.7 %) of individuals with
TB had a centromeric-AA halpotype, compared to only
44.2 % of controls (P = 0.0014). A centromeric-AA
haplotype represents the haplotype with the fewest num-
ber of activating genes. It is hypothesized that this lack
of activating genes may prevent the appropriate release
of M. tuberculosis killing cytokines [8].
A limitation to this study is the lack of longitudinal
data among our LTBI status group. As we do not know
when an individual became LTBI (IGRA positive) it is
possible that some of these individuals went on to
develop primary or secondary TB, however we do not
have access to this data. It is known that these were
healthy individuals with low risk for the development of
ATB. Another limitation is the unknown TB exposure of
our control group (IGRA negative), we can make no
conclusions in regards to the role KIR plays in TB sus-
ceptibility. This group is used as a reference comparison
group for our LTBI and ATB populations.
Conclusions
In summary, major differences can be seen in KIR gene
frequencies across Mtb disease status groups. KIR haplo-
type frequencies differ between these groups as well. The
differences in KIR gene frequencies and/or haplotypes
may result in differential cytokine expression, contributing
to different disease outcomes, and suggest a genetic influ-
ence on Mtb susceptibility and pathogenesis. The skewed
distribution of A-containing centromeric haplotypes (con-
taining fewer activating genes), along with the increased
presence of TB disease in these haplotypes, suggests a cor-
relation. Further investigation is needed to characterize
the subtleties of these differences by way of sequencing of
specific KIR genes and/or KIR-HLA association studies
taking into account different ethnic populations.
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